Burges Salmon advises Edinburgh-based biotech on investment
Reading time: 1 minute
Katie Carter
Burges Salmon has advised Calcivis, a Scottish biotech that aims to revolutionise early-intervention diagnostics in dentistry, on its £5 million investment.
The funding was provided by the Scottish National Investment Bank and IFS Maven Equity Finance, which is managed by Maven Capital Partners and is part of the Investment Fund for Scotland, delivered by the British Business Bank.
The Burges Salmon team advising Calcivis was led by senior associate Katie Carter, partner Danny Lee, solicitor Will Penfold and trainee solicitor Anousha Al-Masoud from the firm’s corporate and M&A team.
Ms Carter said: “Scotland is home to many biotech companies whose cutting-edge technologies are set to revolutionise healthcare and Calcivis is a prime example of that.
“We’re thrilled to have worked once again with the company and to see it grow from strength to strength with this latest investment round supporting its ambitious expansion plans in the UK, Europe and the US, the largest market for medical technology.”
Share this article:
Subscribe to our newsletter to not miss articles like this one:
SUBSCRIBE
